Sironax

Sironax company information, Employees & Contact Information

Explore related pages

Related company profiles:

Sironax is an emerging leader in the discovery and development of transformational therapies that address degenerative diseases affecting longevity, diseases requiring supportive care, and certain rare diseases. The company focuses on mental decline (neurodegeneration) and physical decline (muscular disorders) by targeting three core drivers: dysregulated cell death, uncontrolled inflammation, and disrupted energy homeostasis. Sironax's breakthrough pipeline contains multiple first-in-class and/or potentially best-in-class programs, among which three have entered into clinical stage. Each of these programs demonstrates Sironax’s unique biological insights and mechanistic innovations, with research focus spanning neuroinflammation, axonal degeneration, muscular weakness, epithelial cell death, and metabolic disorders. All these clinical assets at Sironax are de novo designed and synthesized within the company, each of which features distinct chemical scaffold. In parallel to the actively ongoing clinical development, the company also continues to expand its discovery footprint and plans to advance additional programs into the clinic over the next few years. With operations in the U.S., China, Switzerland, and Australia, Sironax presently has 160 employees and is growing. We continue to build our global team of highly skilled chemists, biologists, and clinicians. Along with decades of experience in global pharmaceutical R&D, our team shares a collective vision of shifting the treatment paradigm for degenerative diseases affecting longevity to ultimately improve the lives of millions of patients and their families around the world.
Looking for a particular Sironax employee's phone or email?

Sironax Questions

News

Sironax Announces Key Leadership Appointments to Advance Global Drug Discovery and Development - Yahoo Finance

Sironax Announces Key Leadership Appointments to Advance Global Drug Discovery and Development Yahoo Finance

Sironax Grants Novartis Exclusive Option to Acquire Brain Delivery Platform - citybiz

Sironax Grants Novartis Exclusive Option to Acquire Brain Delivery Platform citybiz

Sironax Named to 2025 Endpoints 11 List of the Most Promising Biotech Startups - Yahoo Finance

Sironax Named to 2025 Endpoints 11 List of the Most Promising Biotech Startups Yahoo Finance

The Endpoints 11: As China biotech rises, Sironax swings big in neurology with A-list backers and global aims - Endpoints News

The Endpoints 11: As China biotech rises, Sironax swings big in neurology with A-list backers and global aims Endpoints News

Stress granule–mediated ZBP1 activation drives necroptotic cell death in non-obstructive azoospermia and testicular aging - PNAS

Stress granule–mediated ZBP1 activation drives necroptotic cell death in non-obstructive azoospermia and testicular aging PNAS

Novartis inks $175M option deal for Sironax’s blood-brain barrier tech - Fierce Biotech

Novartis inks $175M option deal for Sironax’s blood-brain barrier tech Fierce Biotech

Stress granule–mediated ZBP1 activation drives necroptotic cell death in non-obstructive azoospermia and testicular aging - PNAS

Stress granule–mediated ZBP1 activation drives necroptotic cell death in non-obstructive azoospermia and testicular aging PNAS

Sironax identifies SARM1 modulators for axonal degeneration - BioWorld MedTech

Sironax identifies SARM1 modulators for axonal degeneration BioWorld MedTech

Top Sironax Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant